Alliancebernstein L.P. Cuts Position in OraSure Technologies, Inc. (OSUR)

Alliancebernstein L.P. reduced its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 59.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 163,926 shares of the medical instruments supplier’s stock after selling 242,440 shares during the quarter. Alliancebernstein L.P. owned 0.28% of OraSure Technologies worth $2,829,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of OSUR. BlackRock Inc. lifted its position in OraSure Technologies by 127,593.4% during the 1st quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after buying an additional 7,737,261 shares in the last quarter. Renaissance Technologies LLC lifted its position in OraSure Technologies by 22.3% during the 1st quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock worth $66,357,000 after buying an additional 934,700 shares in the last quarter. Vanguard Group Inc. lifted its position in OraSure Technologies by 30.3% during the 1st quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock worth $57,752,000 after buying an additional 1,037,439 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in OraSure Technologies by 15.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,890,048 shares of the medical instruments supplier’s stock worth $37,368,000 after buying an additional 395,374 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in OraSure Technologies by 32.5% during the 2nd quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock worth $31,877,000 after buying an additional 452,642 shares in the last quarter. 92.07% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://sportsperspectives.com/2017/10/12/alliancebernstein-l-p-cuts-position-in-orasure-technologies-inc-osur.html.

In related news, CFO Ronald H. Spair sold 510,112 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the transaction, the chief financial officer now directly owns 208,606 shares of the company’s stock, valued at $4,309,799.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas A. Michels sold 22,923 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. Insiders have sold 717,601 shares of company stock worth $14,977,398 over the last three months. 6.40% of the stock is owned by insiders.

OSUR has been the topic of several analyst reports. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Saturday, September 9th. Jefferies Group LLC reissued a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reissued a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 19th. Stephens reissued an “overweight” rating and set a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Finally, BidaskClub cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. OraSure Technologies currently has an average rating of “Buy” and a consensus target price of $18.04.

Shares of OraSure Technologies, Inc. (NASDAQ OSUR) opened at 22.06 on Thursday. The stock has a 50 day moving average of $21.65 and a 200-day moving average of $17.39. The company has a market capitalization of $1.31 billion, a PE ratio of 40.78 and a beta of 1.55. OraSure Technologies, Inc. has a one year low of $7.09 and a one year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The company had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same period last year, the firm earned $0.07 earnings per share. The firm’s revenue was up 28.1% on a year-over-year basis. On average, equities analysts forecast that OraSure Technologies, Inc. will post $0.48 earnings per share for the current fiscal year.

OraSure Technologies Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply